Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254462 · ClinicalTrials.gov registry record · Phase 4
Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children
A Phase 4 study of Attention Deficit Disorder With Hyperactivity, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 4
- Development phase
- 93
- Enrollment target
- 3
- Study locations
NCT00254462: Completed Phase 4 study of Attention Deficit Disorder With Hyperactivity, sponsored by University of Nebraska.
NCT00254462 is a Phase 4 study of Attention Deficit Disorder With Hyperactivity that has completed, run by University of Nebraska. The registered enrollment target is 93 participants, below the 351-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (74% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00254462, a Phase 4 study of Attention Deficit Disorder With Hyperactivity, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 93 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will evaluate the effectiveness of atomoxetine in reducing the symptoms of attention deficit hyperactivity disorder (ADHD) in young children.
Primary Outcome
Measures 18 symptoms of attention deficit hyperactivity disorder (ADHD). Each symptom rated 0-3, for a minimum total score of 0, and a maximum total score of 54 for the scale. A higher score reflects more severe symptomatology. The inattentive subscale and the hyperactive/impulsive subscale each has a minimum score of 0 and maximum score of 27.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Atomoxetine
- BEHAVIORAL Parent Training
Study Locations (3)
Nebraska
- University of Nebraska Medical Center - Omaha
New York
- New York State Psychiatric Institute - New York
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2005-10-01 |
| Est. Completion | 2008-09-01 |
| Phase | Phase 4 |
What the finished NCT00254462 record still lists
NCT00254462 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 351-participant average among 20 other Attention Deficit Disorder With Hyperactivity trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Attention Deficit Disorder With Hyperactivity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00254462 reports a single indexed study location in Nebraska, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT00254462 about?
NCT00254462 is a clinical study titled "Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children". This study will evaluate the effectiveness of atomoxetine in reducing the symptoms of attention deficit hyperactivity disorder (ADHD) in young children.
What is the current status of trial NCT00254462?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 93 participants. The study started on 2005-10-01. Estimated completion is 2008-09-01.
What conditions does trial NCT00254462 study?
This clinical trial studies the following conditions: Attention Deficit Disorder With Hyperactivity.
What interventions are being tested in trial NCT00254462?
The interventions under investigation include: Placebo (DRUG), Atomoxetine (DRUG), Parent Training (BEHAVIORAL).
Who is sponsoring clinical trial NCT00254462?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00254462 being conducted?
This trial has 3 study locations across Nebraska, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit Disorder With Hyperactivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00254462's enrollment target sits among peer trials
93 12th of 20 higher than 8 of 20 other Attention Deficit Disorder With Hyperactivity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Attention Deficit Disorder With Hyperactivity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Home-based Transcranial Direct Current Stimulation (tDCS) for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
RECRUITING · NA
-
Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Volunteers
ACTIVE NOT RECRUITING
-
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
COMPLETED · Phase 2
-
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · NA
-
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 3
-
Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI